Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia

Inclusion Criteria: 1. Patients or their legal guardians voluntarily participate and sign the Informed Consent Document; 2. Male or female patients aged 18 to 70 years (inclusive); 3. Pathologically and histologically confirmed CD19 + B cell tumors; Patients currently have no effective treatment options, such as chemotherapy or relapse after hematopoietic stem cell transplantation; Or patients voluntarily choose transfusion of anti-CD19 CAR-T cells as the first treatment program; 4. B-cell tumors / lymphomas and B-cell acute lymphoblastic leukemia include the following four types:1) B-cell acute lymphoblastic leukemia;2) Indolent B-cell lymphomas;3) Aggressive B-cell lymphoma; 4) Multiple myeloma; 5. Subjects: (1) Residual lesions remain after treatment and Not suitable for Hematopoietic stem cell transplantation (auto/allo-HSCT); (2) Relapse after Complement receptor 1 (CR1) and unsuitable for HSCT; (3) Patients with high risk factors; (4) Relapse or no remission after hematopoietic stem cell transplantation or cell immunotherapy. 6\. Have measurable or evaluable tumor foci; 7\. Liver, kidney and cardiopulmonary functions meet the following requirements: 1\) Serum glutamic pyruvic transaminase (ALT) and serum glutamic oxaloacetic transaminase (AST) \<3 ×upper limit of normal (ULN);2) Total bilirubin ≤34.2μmol/L;3) Serum creatinine\<220μmol/L;4) Baseline oxygen saturation≥95%;5) Left ventricular ejection fraction（LVEF）≥40%. 8\. Subjects who did not receive Chemotherapy, Radiotherapy, Immunotherapy (immunosuppressive drugs) or other treatment within 4 weeks prior to enrollment; Relevant toxicity≤1 grade before enrollment (except for low toxicity such as hair loss); 9\. Peripheral superficial venous blood flow is smooth, which can meet the needs of intravenous drip; 10\. Clinical performance status of eastern cancer cooperation group (ECOG) score ≤2,Expected survival≥3 months; Exclusion Criteria: 1. Pregnant (urine/blood pregnancy test positive) or lactating women; 2. Planned pregnancy during treatment or within 1 year after treatment, or a male subject whose partner plans pregnancy within 1 year of their cell transfusion; 3. Patients cannot guarantee effective contraception (condom or contraceptives, etc.) within 1 year after enrollment; 4. Active or uncontrollable infection within four weeks prior to enrollment; 5. Patients with active hepatitis B/C; 6. HIV-infected patients; 7. Severe autoimmune or immunodeficiency disorders; 8. Patients are allergic to macromolecule drugs such as antigens or cytokines; 9. Subjects participated in other clinical trials within 6 weeks before enrollment; 10. Systematic use of hormones within 4 weeks prior to enrollment (except for inhaled hormones); 11. Mental illness; 12. Drug abuse/addiction; 13. The investigators consider other conditions unsuitable for enrollment.